Alzheimer's space suffered setbacks in June but drugmakers remain hopeful

6 July 2022

alzheimer-s-neurology-brain-dementia-big

With rapidly increasing worldwide prevalence, Alzheimer’s disease (AD) has been identified as a major global health threat by the international medical community.

However, June was fairly disappointing for the AD space with several companies announcing negative results from clinical trials and other news for pipeline products, found GlobalData. Despite these setbacks, the leading data and analytics company notes that there is still promise for the future of AD treatment and much to be hopeful about in the near future.

GlobalData’s senior neurology analyst Pippa Salter said: “AD is an indication for which the success rate of clinical trials is historically low, and much of the negative news announced last month highlights just how difficult it has been to develop novel drugs for the treatment of this disease. The failures touched a variety of different drug classes - from anti-amyloid agents to anti-psychosis agents.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK